US Patent 11173141 Enalapril formulations
Patent 11173141 was granted and assigned to Azurity Pharmaceuticals on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+277 characters)
Article
Patent abstract
Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111731410
Date of Patent
November 16, 2021
0Patent Application Number
173384360
Date Filed
June 3, 2021
0Official Website
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111731410
Date of Patent
November 16, 2021
0Patent Application Number
173384360
Date Filed
June 3, 2021
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 18 Nov, 2021
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11173141 Enalapril formulations
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11173141
Date of patent
November 16, 2021
Patent application number
17338436
Date Filed
June 3, 2021
Patent primary examiner
Find more entities like US Patent 11173141 Enalapril formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
